FDA Clears Path for Generic Rasuvo Methotrexate Copies
Published Date: 7/22/2026
Notice
Summary
The FDA has decided that RASUVO (methotrexate) solution wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and possibly cheaper for patients who need this medicine. If all rules are met, these generics could hit the market soon, helping more people get access without breaking the bank.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generic Approval Path Opens
The FDA determined on July 22, 2026 that RASUVO (methotrexate) solution, 27.5 mg/0.55 mL, was not withdrawn from sale for reasons of safety or effectiveness. Because of that determination, abbreviated new drug applications (ANDAs) that refer to RASUVO may be approved if they meet all other legal and regulatory requirements, allowing generic manufacturers to seek approval.
Patients Could Pay Less and Get Easier Access
The FDA notice says generic versions of RASUVO could reach the market soon now that ANDAs may be approved; this could make it easier and possibly cheaper for patients who need methotrexate injections (RASUVO, 27.5 mg/0.55 mL) to get the medicine. Any generic entry depends on applicants meeting legal and regulatory requirements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14573 — Food Standards of Identity Modernization; Pasteurized Orange Juice
The FDA is updating the rules for pasteurized orange juice by lowering the minimum sugar content and allowing up to 15% of a new type of citrus juice. This change helps juice makers, especially in Florida, keep up with modern practices without raising costs. The new rules kick in on August 19, 2026, giving producers time to adjust.
2026-14438 — Agency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Requirements
The FDA wants your thoughts on how they collect info about infant formula rules, like labeling, quality checks, and recordkeeping. This affects infant formula makers who must follow these rules and use a new electronic form to report info. You’ve got until September 15, 2026, to share your comments—no cost changes yet, just a chance to improve how info is gathered!
2026-14441 — Agency Information Collection Activities; Proposed Collection; Comment Request; Accreditation Scheme for Conformity Assessment Program
The FDA wants your thoughts on a plan to improve how they check if medical products meet safety rules. This affects companies making medical devices and could change how they prove their products are safe. You’ve got until September 15, 2026, to share your ideas—no cost changes yet, just a chance to help shape the process!
2026-14436 — Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Voluntary Improvement Program
The FDA wants your thoughts on a new plan to collect info from medical device makers who join a Voluntary Improvement Program. This program aims to help companies improve their devices without extra paperwork stress. If you’re involved in making or managing medical devices, you’ve got until September 15, 2026, to share your feedback—no fees, just your voice!
Previous / Next Documents
Previous: 2026-14778 — Notice Pursuant to the National Cooperative Research and Production Act of 1993-Pistoia Alliance, Inc.
The Pistoia Alliance, a group working together on research, just added six new members from the US, Canada, the UK, the Netherlands, and an individual from Massachusetts. One member from Germany left the group. These changes keep the group’s special legal protections in place, and membership is still open for others who want to join.
Next: 2026-14780 — Notice Pursuant to the National Cooperative Research and Production Act of 1993-Mobile Satellite Services Association
The Mobile Satellite Services Association (MSSA) just updated its team by adding Creative5 Inc. from Taiwan and saying goodbye to Simnovus Corporation from North Carolina. These changes keep the group’s special legal protections in place, helping members avoid big antitrust lawsuits except for actual damages. If you’re part of MSSA or thinking about joining, keep an eye out—membership is open and updates will keep coming!